These pummeled ASX healthcare shares have both endured brutal share price declines over the past year.

CSL Ltd (ASX: CSL) shares started the week down 0.6% to $122.61. Despite rebounding 13% over the past month, they’re still down around 51% over the past 12 months. Cochlear Ltd (ASX: COH) shares slipped 0.4% on Monday to $119.00, leaving them up 4% over the past month but down an even steeper 61% over the past year.

So, are these former market darlings now genuine buying opportunities or value traps?

CSL: Waiting for earnings to recover

For decades, this $59 billion ASX healthcare share earned its reputation as one of the ASX’s highest-quality companies, driven by global leadership in plasma therapies and a long history of consistent earnings growth.

That reputation has taken a hit. A series of earnings downgrades, leadership changes, and around US$5 billion of non-cash impairments tied largely to the CSL Vifor acquisition have weighed heavily on investor sentiment.

The latest disappointment came in May, when management guided FY26 revenue of approximately US$15.2 billion and NPAT of around US$3.1 billion, both below market expectations. The company also flagged another US$5 billion of non-cash impairments across FY26 and FY27.

Despite that, analysts aren’t entirely bearish. According to TradingView data, 10 of the 18 brokers covering CSL now rate the stock as a hold, while the remaining eight have buy or strong buy recommendations. The average price target sits at $138.88, implying around 13% upside.

UBS remains among the bulls with a $158 target price, arguing much of the bad news surrounding Vifor is already reflected in the share price. The most optimistic analysts see gains of around 60% over the next year.

Cochlear: A temporary stumble?

April marked one of the toughest periods in Cochlear’s history.

The hearing implant leader shocked investors after reporting weaker-than-expected demand across developed markets and disruption to shipments caused by conflict in the Middle East.

Management of the ASX healthcare share slashed FY26 underlying profit guidance from $435 million-$460 million to just $290 million-$330 million, triggering a one-day share price collapse of more than 40%.

Yet the company’s competitive position remains largely intact. Cochlear still controls roughly half the global cochlear implant market, underpinned by decades of product innovation, clinical expertise, and strong relationships with surgeons worldwide.

Its long-term growth opportunity also remains compelling. More than six million people in developed markets are estimated to be eligible for cochlear implants, but only around 3% have received one.

Broker sentiment is cautious. Hold remains the most common TradingView recommendation, with an average target price of $127.14, implying roughly 7% upside.

However, six analysts still rate the shares as a buy or strong buy, with the highest target suggesting upside of around 43%. Two analysts recommend selling, with the lowest target price implying almost 16% downside.

Foolish takeaway

Both ASX healthcare shares remain global leaders with durable competitive advantages, but they are also working through company-specific challenges that have dented investor confidence.

For long-term investors, the sharp share price falls may present an opportunity. However, neither company has yet fully restored market confidence, meaning patience may be required before either regains its former market-leading status.

The post Down 50%+: Are these ASX healthcare shares finally worth buying? appeared first on The Motley Fool Australia.

More reading

• Could CSL shares double from here? Here’s what the experts think
• Here’s why I’d buy and hold CSL and Cochlear shares for 10 years
• Here’s what brokers tip for CSL shares over the next 12 months
• How have CSL shares performed over 10 years?
• Cochlear shares have bounced 16%. Should you buy, hold, or sell now?

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

It’s never too early to start saving for retirement, and the good news for parents who want to give their children a head start is that, yes, it is possible to set up a superannuation fund for your children.

Superannuation fund selection is the first step

Depending on your child’s age, you might need to shop around to find a fund that allows you to set up accounts for children.

UniSuper, for example, only allows funds to be set up for people aged 15 and above.

Student Super, on the other hand, allows a fund to be set up at any age and charges no administration fees for balances under $1000.

The fund’s Golden Goose Gifting program was specifically set up to make it easy for parents and grandparents to put money into a child’s superannuation account.

Student Super Chief Executive Officer Andrew Moloney says in a video on the fund’s website that Australians generally set up a super fund at about the age of 20, but by setting up a fund early, the benefits of compound interest can accrue for around two decades longer.

In order to set up and contribute into a superannuation fund for a child, it’s necessary to set up a tax file number (TFN) for the child also.

Student Super’s website says, “Once the child’s TFN is added to their account, the parent or guardian will be able to access the details to make a contribution to the child’s super account”.

The magic of compound interest

And the benefits are significant. $1000 contributed when a child is born, compounded over 20 years at 8%, turns into $4661, as calculated on the Moneysmart compound interest calculator.

If $1000 more is added each year, this figure grows to $50,423.

And this isn’t counting the contribution that the Federal Government will make to your child’s super account.

The government makes a co-contribution to superannuation for low-income earners of $500, as long as $1000 in non-concessional (after tax) contributions are made.

As the ATO says:

You don’t need to apply for the super co-contribution. When you lodge your tax return, we will work out if you’re eligible. If your super fund has your tax file number (TFN), we will pay it to your super account automatically.

If $1500 is compounded at 8% over 20 years, the result is $6991; if $1500 is contributed each year for 20 years, the result is a whopping $75,634.

That’s quite the head start, and while super is usually tied up until retirement age, the personal contributions can be withdrawn and used to buy a home under the government’s First Home Super Saver Scheme.

The post How to give your child a $75,000 superannuation head start appeared first on The Motley Fool Australia.

More reading

• Down 50%+: Are these ASX healthcare shares finally worth buying?
• Chemist Warehouse: Are Sigma Healthcare shares a buy, hold, or sell?
• Here are the top 10 ASX 200 shares today
• Are Westpac shares a top buy this week?
• Ophir High Conviction Fund announces FY26 unfranked distribution

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Bell Potter has been busy running the rule over the Grattan Institute report this month relating to the pharmacy industry.

The broker notes that if the changes suggested were put in place there could be significant implications for Chemist Warehouse owner Sigma Healthcare Ltd (ASX: SIG).

What is in the report?

Bell Potter highlights that the Future Pharmacy report shines light on the inefficiencies of the funding and other arrangements for Community Pharmacy (CP) in Australia. 

It notes that if “either side of politics to embrace the deregulation measures as recommended, earnings patterns for SIG and many of the pharmacies whose earnings are preserved by this pharmacy gerrymander would change forever.”

Commenting on the report, Bell Potter said:

The Grattan report identifies numerous inefficiencies within Australia’s system for CP including pharmacy remuneration and the opacity of data supporting the current structure, however, maximum venom is reserved for the pharmacy ownership laws and location rules. 

The rules are no longer fit for purpose and now act as a handbrake to further competition while preserving the earnings stream of incumbents. The rules also prevent the participation of supermarkets in CP for reasons that are less clear with each passing year.

Thankfully for Sigma Healthcare and its shares is that Bell Potter believes any potential changes to regulations would still be a long way off. It adds:

Whether the Grattan report influences change remains to be seen, however, CP is probably a long way down the Federal Government’s priority list for reform. Additionally, reform in this section of the market is unlikely to generate momentum on polling day, particularly if the Guild and AMA oppose changes as history suggests is likely. For these reasons, the regulatory environment supporting Community Pharmacy and the likes of Sigma Healthcare are unlikely to change.

Should you buy Sigma Healthcare shares?

According to the release, Bell Potter has retained its hold rating and $3.00 price target on the company’s shares. This is just a touch above its current share price of $2.93.

Commenting on its hold rating, the broker said:

Regulatory upheaval in CP is unlikely, nevertheless, investment metrics for SIG are not sufficiently attractive to warrant a Buy rating, particularly with a single payer (the Federal Government) representing a disproportionate level of group revenue. 

The Government’s propensity to alter funding arrangements on short notice with little industry consultation should elevate the risk rating on SIG. We maintain our Hold rating and PT $3.00.

The post Chemist Warehouse: Are Sigma Healthcare shares a buy, hold, or sell? appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Sigma Healthcare, Wisetech Global, CBA shares
• 3 reasons why the ASX share owner of Chemist Warehouse is a buy
• Leading brokers name 3 ASX shares to buy today
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) endured a bumpy and ultimately negative start to the week’s trading this Monday. After remaining in positive territory for most of today’s session, investors ended up getting cold feet right before the closing bell. After that collapse in confidence, the ASX 200 ended up finishing down 0/061%, leaving the index at 8,791.3 points.

This rather indecisive session for the Australian markets came after an even nastier end to the American trading week on Friday night (our time).

The Dow Jones Industrial Average Index (DJX: .DJI) had another tough session, dropping 0.77%

The tech-heavy Nasdaq Composite Index (NASDAQ: .IXIC) fared even worse, falling a horrid 1.4%.

But let’s get back to this week and our local markets now and take a closer look at what was happening amongst the different ASX sectors today.

Winners and losers

Tech shares were the sector that was singled out for punishment this Monday. The S&P/ASX 200 Information Technology Index (ASX: XIJ) was slammed, tumbling 1.54%.

Utilities stocks fared better, but the S&P/ASX 200 Utilities Index (ASX: XUJ) still tanked by 0.63%.

Healthcare shares were in a similar boat. The S&P/ASX 200 Healthcare Index (ASX: XHJ) saw its value dive 0.49% today.

Mining stocks weren’t popular either, evident by the S&P/ASX 200 Materials Index (ASX: XMJ)’s 0.34% dip.

Gold stocks were also no safe haven. The All Ordinaries Gold Index (ASX: XGD) ended up sinking 0.23%.

Real estate investment trusts (REITs) followed right behind gold, with the S&P/ASX 200 A-REIT Index (ASX: XPJ) dipping 0.17%.

Our last losers this Monday were financial stocks. The S&P/ASX 200 Financials Index (ASX: XFJ) slipped 0.07% by the closing bell.

Let’s turn to the winning sectors now. Leading the charge were energy stocks, illustrated by the S&P/ASX 200 Energy Index (ASX: XEJ)’s 1.8% surge.

Consumer staples stocks also ran hot. The S&P/ASX 200 Consumer Staples Index (ASX: XSJ) roared 0.43% higher this session.

Communications shares saw high demand too, with the S&P/ASX 200 Communication Services Index (ASX: XTJ) lifting 0.39%.

Industrial stocks came next. The S&P/ASX 200 Industrials Index (ASX: XNJ) advanced 0.16% today.

Finally, consumer discretionary shares got themselves over the line, as you can see by the S&P/ASX 200 Consumer Discretionary Index (ASX: XDJ)’s 0.11% bump.

Top 10 ASX 200 shares countdown

Today’s winner was healthcare share 4DMedical Ltd (ASX: 4DX). 4DMedical shares soared 7.19% higher this session to close at $3.43 each. This may have been a reaction to last week’s announcement.

Here’s the rest of today’s best: 

ASX-listed company	Share price	Price change
4DMedical Ltd (ASX: 4DX)	$3.43	7.19%
Deep Yellow Ltd (ASX: DYL)	$1.31	6.10%
Yancoal Australia Ltd (ASX: YAL)	$5.68	5.97%
South32 Ltd (ASX: S32)	$4.08	4.62%
Pantoro Gold Ltd (ASX: PNR)	$2.00	4.18%
Graincorp Ltd (ASX: GNC)	$5.23	4.18%
Viva Energy Group Ltd (ASX: VEA)	$2.43	3.85%
AMP Ltd (ASX: AMP)	$2.09	3.47%
New Hope Corporation Ltd (ASX: NHC)	$5.38	2.87%
Whitehaven Coal Ltd (ASX: WHC)	$7.63	2.69%

Our top 10 shares countdown is a recurring end-of-day summary that shows which companies made big moves on the day. Check in at Fool.com.au after the weekday market closes to see which stocks make the countdown.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: SKS Technologies, Yancoal, Wesfarmers shares
• Why South32 shares edge higher on strong results and landmark deal
• South32 reveals FY26 operating results
• Deep Yellow announces major construction contracts for Tumas Project
• Fletcher Building secures $60m for local cement production in NZ

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Westpac Banking Corp (ASX: WBC) shares have pulled back from their recent highs, which may tempt investors who missed the earlier run.

The fully franked dividend also remains appealing.

But has the lower share price created one of the best buying opportunities on the ASX this week?

A fair price rather than a bargain

Westpac shares are trading around $36.66.

According to consensus estimates, this puts the shares on a price-to-earnings ratio of around 17.2 times FY26 earnings and 17.1 times FY27 earnings.

Those multiples are far from outrageous, particularly for a major bank with a large customer base and a strong capital position.

The forecast dividend adds more weight to the investment case.

Consensus estimates are for dividends per share of $1.54 in FY26 and $1.55 in FY27, giving Westpac forward dividend yields of approximately 4.2% in both years. Those dividends are expected to be fully franked, which could improve the after-tax income for eligible investors.

I can understand why that combination would attract income-focused shareholders.

Westpac is making progress

I think the investment case has improved under CEO Anthony Miller.

Westpac has been growing across mortgages, business lending, and deposits, while also trying to reduce unnecessary complexity across the company. Its first-half result showed continued lending momentum, lower costs compared with the previous half, and a capital position comfortably above management’s target.

I also like the opportunity in business banking. Relationships with business customers can extend across lending, deposits, payments, equipment finance, working capital, and transaction services. That can make them deeper than a standard home loan relationship and provide several ways for Westpac to earn revenue.

The UNITE technology program could also leave Westpac with a simpler and more efficient bank. Bringing systems and processes together should eventually improve the customer experience and reduce duplication, although a transformation of this size will require careful execution.

Why I am staying selective

The biggest issue for me is the limited earnings growth currently expected.

Consensus estimates suggest EPS will rise only slightly between FY26 and FY27. At around 17 times forecast earnings, I do not think investors are being offered enough of a discount to compensate for that modest outlook.

Banking also remains intensely competitive. Westpac must fight for mortgages and deposits while investing heavily in technology, meeting regulatory requirements, and preparing for credit losses if economic conditions weaken.

Foolish takeaway

Westpac is heading in a better direction, and the recent share price weakness has improved the entry point.

Existing shareholders have good reasons to remain patient while collecting a fully franked dividend. Income investors may also find the forecast yield attractive enough to begin a measured position.

Even so, I would not call Westpac shares a top buy this week. The valuation looks fair rather than cheap, while forecast earnings growth remains subdued.

For me, Westpac is a hold at current prices and a potential buy after a further pullback.

The post Are Westpac shares a top buy this week? appeared first on The Motley Fool Australia.

More reading

• If I invest $10,000 in Westpac shares, how much passive income will I receive in 2027?
• What are experts tipping for the big four bank shares in the back half of 2026?
• How much passive income can I earn off a $50,000 portfolio?
• ANZ, NAB, Westpac and CBA shares: Brokers rate 2 a sell, and 2 a hold
• 3 of the best ASX dividend stocks to supplement your superannuation

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Ophir High Conviction Fund (ASX: OPH) share price is in focus today after announcing its full-year unfranked distribution of 36.33 cents per unit, with payment due on 17 August 2026.

What did Ophir High Conviction Fund report?

• Full year unfranked distribution of 36.33 cents per unit
• Distribution relates to the period ending 30 June 2026
• Record date is 1 July 2026; ex-date is 30 June 2026
• Payment scheduled for 17 August 2026
• Distribution Reinvestment Plan (DRP) available to eligible unitholders with a zero discount

What else do investors need to know?

This distribution is entirely unfranked, reflecting current taxation arrangements for the fund. The DRP allows eligible investors—those based in Australia and New Zealand—to reinvest their distributions into additional units, with the reinvestment price to be based on the fund’s net asset value during the calculation period.

Unitholders who do not elect to participate in the DRP will receive their distribution as a cash payment. Final tax component details will be provided in standard AMMA statements following 30 June.

What’s next for Ophir High Conviction Fund?

Looking ahead, management is expected to continue focusing on delivering value to unitholders and communicating distribution details clearly. Eligible investors may choose to reinvest or receive distributions as cash, depending on their individual circumstances. The fund will update the market on any changes to future distributions or fund strategies as needed.

Ophir High Conviction Fund share price snapshot

Over the past 12 months, Ophir High Conviction shares have declined 19%, trailing the S&P/ASX All Ords Index (ASX: XAO), which has risen 2% over the same period.

View Original Announcement

The post Ophir High Conviction Fund announces FY26 unfranked distribution appeared first on The Motley Fool Australia.

More reading

• 5 ASX All Ords shares that ripped 200% to 400% in FY26
• Targeting a dividend yield above 10%? Try these shares on for size

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

S&P/ASX Small Ordinaries Index (ASX: XSO) shares are in the green on Monday, up 0.5% to 3,323.9 points.

ASX small-cap shares outperformed in FY26. The index rose 5.46% and delivered a total return, including dividends, of 8.11%.

This compares with a 2.43% rise and a 5.69% total return for the S&P/ASX All Ordinaries Index (ASX: XAO).

This week, experts are calling time on three ASX small-cap shares.

Let’s find out why (courtesy The Bull).

Judo Capital Holdings Ltd (ASX: JDO)

The Judo share price is 95 cents, up 1.3% on Monday and down 39% over 12 months.

The ASX small-cap bank share took a big hit last month after Judo issued a profit guidance downgrade.

Mark Elzayed from Investor Pulse explains his sell recommendation on Judo Capital shares:

Judo recently cut profit before tax guidance in fiscal year 2026 to between $163 million and $169 million from a previous range of between $180 million and $190 million.

It was primarily driven by a higher cost of risk now expected to range between $116 million and $122 million following specific provisions against three exposures across different sectors.

Profit before tax guidance of between $210 million and $220 million in full year 2027 was below market expectations of $255.1 million.

In our view, market reaction reflects more than a one-off potential earnings downgrade.

Provisioning risk remains elevated, so we retain a sell on Judo Capital.

Forrestania Resources Ltd (ASX: FRS)

The Forrestania Resources share price is 38 cents, down 3.8% today but up 192% over 12 months.

Elzayed also gives this ASX small-cap materials share a sell rating, and commented:

FRS is a gold exploration and development company focusing on building quality projects across Western Australia’s mining districts.

FRS announced on July 1 it had received binding commitments to raise about $310 million for the Edna May Gold Hub. The company’s objective is to have Edna May fully commissioned and operational in the first half of 2027.

An institutional placement of 775 million shares was priced at 40 cents. The placement is shareholder dilutive and gold prices remain under pressure, in our view.

The shares have fallen from 64 cents on May 18 to trade at 39 cents on July 15.

Readytech Holdings Ltd (ASX: RDY)

The Readytech share price is $1.61, down 0.3% today and and down 33% over 12 months.

Nathan Lodge from Securities Vault explained his sell rating on this ASX small-cap tech share:

An unsolicited, non-binding indicative proposal to acquire ReadyTech Holdings was rejected by the RDY board on June 1, 2026.

The RDY board concluded that the $2 a share cash scheme arrangement and a parallel off market bid of $1.75 a share didn’t reflect the company’s inherent value and wouldn’t be executable. The shares were trading at $1.61 on July 15.

ReadyTech has built a quality software business with recurring revenue across education, workforce management and government solutions.

However, I believe much of the company’s long term growth potential is already reflected in the share price, limiting scope for further upside in the near term. ReadyTech operates in highly competitive markets.

The post Sell Judo shares and 2 other ASX small-caps: experts appeared first on The Motley Fool Australia.

More reading

• 2 ASX shares tipped to grow 45% or more in the next 12 months
• 5 things to watch on the ASX 200 on Tuesday
• This ASX gold stock could rocket 200%+ after ‘transformational’ deal
• 9 ASX 200 shares downgraded by analysts this week
• 3 ASX 200 shares with 50% to 100% upside in FY27

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ReadyTech. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are up 0.14% to 8,808.6 points on Monday afternoon. 

The fastest rising ASX 200 shares today are 4D Medical Ltd (ASX: 4DX), up 10%, and Deep Yellow Ltd (ASX: DYL), up 7.3%.

Among the biggest fallers are Alcoa Corporation CDI (ASX: AAI), down 3.8%, and Pexa Group Ltd (ASX: PXA), down 3.6%.

Let’s check out 3 shares with new ratings from the experts today (courtesy The Bull). 

SKS Technologies Group Ltd (ASX: SKS)

The SKS Technologies share price is $7.95, down 5% today but up 250% over 12 months.

Mark Elzayed from Investor Pulse has a buy rating on this ASX 200 industrials share. 

He said: 

SKS specialises in electrical technologies and digital infrastructure. It offers services across audio visual, communications and electrical solutions in Australia.

In our view, it’s a compelling buy in response to Australia’s data centre electrification boom.

Sales revenue rose 13.6 per cent in the first half of 2026 when compared to the prior corresponding period, while profit before tax increased 52.8 per cent. EBITDA was up 42.9 per cent.

The company is forecasting full year revenue of $340 million in full year 2026 at a profit before tax margin of 10 per cent.

The forecast is underpinned by a robust order book and the Delta Elcom acquisition expanding its Sydney data centre footprint and representing a significant percentage of the domestic market.

Yancoal Australia Ltd (ASX: YAL)

The Yancoal share price is $5.69, up 6.1% today and down 6.5% over 12 months.

The coal producer is the third fastest-rising share of the ASX 200 today.

Elzayed has a hold rating on this ASX 200 energy share. 

He explained:  

Yancoal is balancing strong fundamentals against a near term overhang.

In April, YAL announced it would acquire 80 per cent of the Kestrel metallurgical coal mine in the Bowen Basin for $US2.4 billion. The acquisition is accretive over the long term, but adds leverage.

Diesel cost inflation threatens to push 2026 unit costs toward the top end of its guidance range.

Consensus targets of about $7.02 on July 15 imply upside, but integration and coal price risks argue for holding the stock rather than adding.

Wesfarmers Ltd (ASX: WES) 

The Wesfarmers share price is $92.64, down 0.2% today and up 10.6% over 12 months.

Tony Locantro from Alto Capital has a sell rating on the ASX 200’s largest consumer discretionary share.

He said:

The company delivered a strong first half result in full year 2026, reporting net profit after tax of $1.603 billion, up 9.3 per cent, reflecting continued earnings growth across its retail portfolio amid disciplined operational execution.

Despite these strong fundamentals, much of the company’s quality and long term growth outlook appear fully reflected in its premium valuation.

While Wesfarmers remains an outstanding long term business, future upside may be constrained by elevated market expectations.

Given the strong share price performance and demanding valuation, the current risk-reward balance supports taking profits at current levels.

The post Buy, hold, sell: SKS Technologies, Yancoal, Wesfarmers shares appeared first on The Motley Fool Australia.

More reading

• Deep Yellow announces major construction contracts for Tumas Project
• These are the 10 most shorted ASX shares
• How much is needed in superannuation to target a $100,000 annual passive income?
• Should you buy, hold, or sell Wesfarmers shares?
• Alcoa smashes Q2 revenue record, boosts portfolio with South32 acquisition

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Wesfarmers. The Motley Fool Australia has recommended Sks Technologies Group and Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are up 0.16% to 8,810.5 points on Monday.

Among the 11 market sectors, energy is in the lead today, up 1.9%.

The technology sector is the laggard, down 1.1%.

Let’s check out some new ratings on three ASX 200 shares.

Wisetech Global Ltd (ASX: WTC)

The Wisetech share price is $33.88, down 3.1% today and down 71% over 12 months.

Bell Potter has a buy rating on this ASX 200 tech share with a 12-month target price of $71.75.

Analyst Chris Savage said: 

There has been a tech rally of sorts on the ASX over the past couple of months and this has been led by some of the large cap names including Pro Medicus Ltd (ASX: PME), Block CDI (ASX: XYZ) and Life360 Inc (ASX: 360).

One large cap which has not rallied, however, is WiseTech and this is likely due to a number of factors including further negative press reports around founder and Chief Innovation Officer Richard White, concern around the potential future loss of key customer DSV and risk around both the FY26 result and FY27 guidance and whether each meets market expectations.

In our view, however, these negatives will start to dissipate over the coming months and indeed have already commenced with
the appointment earlier this month of Raelene Murphy to Chair which we regard as a positive move.

Sigma Healthcare Ltd (ASX: SIG)

The Sigma Healthcare share price is $2.94, up 0.2% today and up 7% over 12 months.

Bell Potter has a hold rating on this ASX 200 healthcare share with a price target of $3.

Analyst John Hester said: 

… investment metrics for SIG are not sufficiently attractive to warrant a Buy rating, particularly with a single payer (the Federal Government) representing a disproportionate level of group revenue.

The Government’s propensity to alter funding arrangements on short notice with little industry consultation should elevate the risk rating on SIG.

Commonwealth Bank of Australia (ASX: CBA)

CBA shares are $172.73 apiece, up 0.6% today and down 3% over 12 months.

Morgans has a sell rating on CBA shares and just reduced its 12-month target from $119.40 to $117.63.

Analyst Nathan Lead said:

We make updates to our forecasts ahead of the FY26 result in August. Net result is 1-2% downgrades to FY27-28F EPS.

Sell retained, given stretched valuation metrics remain implied in the share price (c.26x PER, 3.7x PBV, 2.9% cash yield).

The post Buy, hold, sell: Sigma Healthcare, Wisetech Global, CBA shares appeared first on The Motley Fool Australia.

More reading

• Why WiseTech shares could rocket 100%
• 5 things to watch on the ASX 200 on Monday
• If I invest $10,000 in Westpac shares, how much passive income will I receive in 2027?
• Buy, hold, sell: BHP, CBA, and Rio Tinto shares
• How to make $50,000 of passive income from ASX shares like CBA

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Block, Life360, and WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Life360 and WiseTech Global. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 300 Index (ASX: XKO) tech stock Weebit Nano Ltd (ASX: WBT) has delivered some smashing gains over the past 12 months.

In early afternoon trade on Monday, shares in the semiconductor memory technology company are changing hands for $5.62 apiece.

This sees the Weebit Nano share price up a very impressive 148.7% over the last year, racing ahead of the 1.3% 12-month gains delivered by the benchmark index.

And looking ahead, Investor Pulse’s Mark Elzayed believes the stock is well-placed to keep outperforming (courtesy of The Bull).

Here’s why.

Should I buy the ASX 300 tech stock today?

“Weebit Nano develops advanced semiconductor memory technology,” Elzayed noted late last week.

Commenting on his bullish outlook for the ASX 300 tech stock, he said:

Licensing deals with Texas Instruments and onsemi have contributed to company performance. Revenue guidance of $10 million in full year 2026 and a recent capital raising of $102 million fortifies the balance sheet for artificial intelligence and research development.

Indeed, in a market announcement out just this morning, Weebit Nano again upgraded its full year revenue guidance.

According to the release:

Based on unaudited numbers, the company now expects revenue to be at least A$13.5 million, replacing previous guidance of “at least A$12 million”. The increased revenue guidance is mainly attributable to the expansion of customer projects.

Summarising his buy recommendation on Weebit Nano shares, Elzayed concluded:

The shift towards a recurring royalty model generates long term operating leverage. Momentum and news flow are positive, although the multi-year path from licence to royalty income remains the key execution risk.

What’s the latest from Weebit Nano?

The ASX 300 tech stock reported its third quarter (Q3 FY 2026) results on 30 April.

Commenting on the company’s upgraded full year revenue guidance at the time, Weebit Nano CEO Coby Hanoch said, “It’s been an important quarter for Weebit Nano as we made the strategic decision to significantly strengthen our balance sheet to accelerate our growth ambitions.”

Hatch noted:

Our technology was selected for a Korean National Compute-in-Memory program, we secured two new revenue-generating agreements, and continued to make strong technical progress with onsemi and Texas Instruments.

As for the recent capital raising the Elzayed mentioned above, Hatch said:

The added capital from our recent raise enables us to widen the gap between ourselves and competitors and have undisputedly the best ReRAM in the market. As the only independent provider of qualified ReRAM, we have a once-in-a-generation opportunity to take share as adoption shifts from niche to mainstream.

The post Up 149% in a year, why this surging ASX 300 tech stock is still a good buy today appeared first on The Motley Fool Australia.

More reading

• 5 ASX All Ords shares that ripped 200% to 400% in FY26
• These are three of the hottest ASX shares right now – can they keep rising?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.